Healio,Hillier told reporters during a virtual HIV prevention meeting that Islatravir was “extremely potent [with] an extremely long half-life.“Which means that it’s a long-acting agent that can be used for prevention or treatment.”Related: 5 ways to get PrEP delivered to your doorstepIn its phase 2 trial, 250 participants at low-risk of HIV were recruited to receive either six monthly doses of Islatravir or a placebo.Those taking Islatravir were monitored to see how quickly the medicine entered their bodies and how long it remained potent.The Islatravir participants were found to have levels of the drug, “well above the prespecified PK threshold for HIV-1”.Further investigation revealed “rapid, sustained and adequate distribution”.